54 results about "Keloid" patented technology

The present invention discloses a polypeptide combination wound healing preparation with high permeability, specifically relating to a polypeptide combination of tripeptide-1, hexapeptide-9, and palmitoyl-modified peptide, and a new use for treating skin diseases such as wounds, ulcers, burns, scars, and keloids. While the polypeptide combination plays a significant synergistic effect in wound healing, it can effectively prevent and inhibit scar hyperplasia. In addition, the polypeptide combination wound healing preparation of the present invention utilizes the wound healing promoting activity of the composite polypeptide, and is compounded with specific penetration enhancers and antioxidants to be prepared into a gel with functions of moisturizing, promoting healing, reducing infection, and relieving pain, greatly increasing skin penetration, significantly enhancing the skin retention dose, and having significant antibacterial, anti-inflammatory, eschar-removing and muscle-generating, astringent healing, and scar hyperplasia inhibiting effects, being particularly suitable for wound healing and reducing scar residue.

The invention discloses application of BAG2 as a drug target and an inhibitor thereof in preparation of a drug for treating keloid. The protein BAG2 specifically expressed by keloid fibroblasts is found through analysis of single cell data of keloid and normal skin. Through in-vitro experiments, BAG2 expression is inhibited, keloid fibroblast proliferative activity and collagen expression are significantly inhibited, and cell infiltration is also significantly weakened. A small molecule drug for targeted inhibition of BAG2 is further obtained through small molecule drug library screening and in-vitro experiments, so that the purpose of accurate and efficient treatment of keloids is achieved.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The invention discloses a genetic locus marker combination for diagnosis or prognosis evaluation of keloid susceptible population as well as a detection method and application of the genetic locus marker combination, and belongs to the field of detection, and genetic loci comprise the following loci: rs873549, rs1442440, rs2271289, rs17431184 and rs2299939. According to the invention, the genetic susceptibility of Keloid keloid in North China can be comprehensively predicted according to genotype detection results of the selected five gene loci. Therefore, targeted treatment on the patient is achieved, and the curing possibility of the patient is improved.

A method of producing a rapamycin-containing composition for treating skin disease, which comprises the steps of dissolving rapamycin in an ethanol-containing solvent, adding a gelling and / or thickening agent to the resulting rapamycin-containing solution, and adjusting the pH of the resulting rapamycin-containing composition to 5.5 to 6.1 with triethanolamine or tris(hydroxymethyl)aminomethane (TRIS) is provided. A method of inhibiting degradation of rapamycin in a rapamycin-containing composition for treating skin diseases, wherein the method comprises the step of adjusting the pH of the composition to 5.5 to 6.1 with triethanolamine or tris(hydroxymethyl)aminomethane is also provided. A rapamycin-containing composition for treating skin diseases comprising (i) rapamycin, (ii) carboxylic acid-containing aqueous polymer, and (iii) at least one pH adjuster selected from triethanolamine and tri(hydroxymethyl)aminomethane, having a pH of 5.5 to 6.1 is also provided. The carboxylic acid-containing polymer may be carboxy vinyl polymer (carbomer), carboxymethyl cellulose or carboxyethyl cellulose. The skin disease may be dermatitis, contact dermatitis, psoriasis, atopic dermatitis, seborrheic dermatitis, nummular eczema, vitiligo, keloids, autosensitised dermatitis, stasis dermatitis, sebaceous deficiency eczema, skin tumours of tuberous sclerosis, and skin tumours of Recklinghausen’s disease. Preferred topical gels comprise rapamycin, carboxy vinyl polymer (carbomer), ethanol, water and either triethanolamine or tris(hydroxymethyl)aminomethane.

The utility model relates to the technical field of medical rehabilitation appliances, in particular to an upper limb pressure belt for treating neonatal keloids, which comprises an upper limb bandage, an adhesive tape is arranged on the left side of the front of the upper limb bandage, and magic tapes extending along the length direction of the upper limb bandage are adhered to the top and the bottom of the front of the upper limb bandage. Two groups of hook-and-loop fasteners are arranged on the front face of the upper limb binding band, an interlayer pocket is arranged on the front face of the upper limb binding band and located between the two groups of hook-and-loop fasteners, a warm heating wire is sewn in the interlayer pocket, and an inflatable bag piece is attached to the front face of the upper limb binding band. Hot compress treatment can be selectively conducted on the new keloid in the pressure binding process, the new keloid can be softened through hot compress, and therefore the purpose of fading scars can be achieved.

The invention provides a keloid disease in-vitro model as well as a construction method and application thereof, and relates to the technical field of cell biology. The construction method comprises the following steps: constructing a full-thickness skin model with an epidermal layer and a corium layer by utilizing a cell culture chamber or a cell culture micro-fluidic chip, and then performing induced culture by adopting TGF-beta to obtain the keloid disease in-vitro model. According to the construction method, by selecting the concentration and culture time of TGF-beta in the induction process, keloid-like change of the full-thickness skin model can be effectively promoted, and the pathological state of keloid is truly simulated; meanwhile, the human fibroblasts and the human keratinocytes are adopted to prepare the in-vitro model with the full-thickness skin structure, the in-vitro model has the human attribute, the individual difference of species difference bases is reduced, and the real effectiveness of the model is greatly improved; the defect that keloid which is a special human disease cannot be effectively simulated by an animal model is overcome.

The application provides a construction method of a humanized keloid mouse model, comprising the following steps: BAC plasmid construction and preparation; superovulation of experimental mice and collection of zygotes; pronuclear microinjection of zygotes; post-injection embryo transplantation; genotype identification; breeding and genetic analysis; and verification of construction results of the humanized immune system by immunohistochemistry and immunofluorescence. In the application, peripheral blood mononuclear cells treated by sCD27 and skin around keloids (homologous cells and tissues) are transplanted into NSG-MHC-DKO immune-deficient mice with overexpression of CD70 genes, so that HLA rejection of different homologous immune cells and tissues can be avoided, the internal microenvironment of keloids and the interaction between the internal microenvironment and the immune system can be restored to the maximum extent, and the influence of immune factors on the occurrence and development of keloids can be realized in vitro. The application first discovers and verifies that the activation of the CD27-CD70 axis can promote the occurrence and development of keloids, and provides a suitable animal model for the research and development of anti-keloid drugs, especially immunotherapy.

The utility model discloses an indwelling injection treatment device, and relates to the technical field of medical instruments, the indwelling injection treatment device is used for keloid treatment, the indwelling injection treatment device comprises a shell, an injection device and a plurality of fixing bands, the shell is provided with a cavity with a bottom opening; the injection device is located in the cavity and comprises a liquid storage barrel and at least one indwelling needle, the liquid storage barrel is used for storing liquid medicine, the indwelling needle is communicated with the liquid storage barrel, the indwelling needle is arranged towards the opening of the shell, and the indwelling needle is used for being indwelled in scar tissue; the injection device is used for injecting liquid medicine into scar tissues; the fixing band is detachably connected with the shell, and the fixing band is used for fixing the shell on the scar tissue. The keloid injector aims at enabling a keloid patient to perform injection operation at home without going back and forth to a hospital for many times.

The present specification discloses a method, system, and apparatus for inhibiting collagen production in fibroblasts using an alternating electric field. In one aspect, the present invention can effectively regulate ECM homeostasis by inhibiting the production of type I procollagen and increasing MMP-1 expression using a low-frequency and low-intensity alternating electric field, thereby effectively regulating (inhibiting) collagen production in fibroblasts. In another aspect, it has the advantage of being applicable not only to the treatment of fibroproliferative skin diseases such as hypertrophic scars and keloids, but also to the prevention and treatment of general surgical wounds that occur after surgery.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

There is disclosed a wound treatment system having an ampoule with at least two chambers for housing a first and second-containing elastomer component respectively. The ampoule is closed at one end and is sealed at the other end via a tab-seal. Once the tab-seal is removed, a cap is secured to the anterior end of the ampoule via engagement members. The cap is configured with a mixing member found in a channel that runs the length of the cap. As a user applies a lateral force to the ampoule, the first and second-containing elastomer components are mixed by the mixing member to form a skin treatment composition that is applied to the skin of a user for treating a burn, a wound, a scar or a keloid.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation in the skin, e.g., atopic dermatitis, eczema other than atopic dermatitis, hidradenitis suppurativa, vitiligo, alopecia areata, scleroderma (including systemic sclerosis), dermatomyositis, epidermolysis bullosa, mastocytosis, keloids, acne, rosacea, or bullous pemphigoid, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody (Afimkibart).

The invention relates to the technical field of keloid resection, and discloses a minimally invasive surgery device for keloid core resection, which comprises a body, and further comprises an outer sleeve fixedly connected to the front end of the body, the outer sleeve is of a slender hollow structure and is used for being inserted into keloid tissues through a skin tiny incision; the inner cutting tube is coaxially arranged in the outer sleeve and can rotate relative to the outer sleeve, and an annular cutting edge used for cutting keloid fibrous tissue is formed at the far end of the inner cutting tube; according to the minimally invasive surgery device for keloid core excision, the outer sleeve and the inner excision tube are coaxially arranged, and the annular cutting edge used for cutting keloid fibrous tissue is formed at the far end of the inner excision tube, so that the device can enter the keloid through a tiny incision of the skin; on the premise of reducing skin wounds, effective treatment of keloid core tissues is realized, and improvement of postoperative healing effect and appearance recovery are facilitated.

A suspension formulation of nanoparticles of clobetasol propionate is described. The suspension can be therapeutically used for treating skin and eye burns; wound healing is enhanced; preventing or reducing hypertrophic scabs / keloids; the traditional Chinese medicine composition is used for treating allergic rhinitis / nasosinusitis, asthma, inner ear diseases including hearing loss, tinnitus or dizziness, tenosynovitis, tendinitis, puncturitis or arthritis.

The disclosure relates to methods of treating and / or preventing scarring that would otherwise result from an incision to an area of skin. The methods comprise administering a composition comprising tropoelastin to an area of skin that is to receive an incision and / or after the incision. It is also contemplated that the compositions may reduce scar discoloration. Methods of preventing or reducing keloid re-occurrence are also provided.

The application of bazedoxifene as an active ingredient in the preparation of a drug for blocking the differentiation of fibroblasts of the IL-6 family / gp130 signal axis. It has been verified that in the microenvironment of skin tissue, the early or very early appearance of pro-fibrotic stimulating factors (such as IL-11 and / or IL-6) can significantly inhibit the initiation of the pro-fibrotic molecular program, avoid the abnormal activation of myofibroblasts, thereby inhibiting the differentiation of fibroblasts into myofibroblasts, and can effectively inhibit the fibroblast migration of skin fibroblasts induced by pro-fibrotic stimulating factors (especially IL-11), effectively prevent skin fibrosis, and thereby prevent the formation of keloid.

The invention relates to the field of biological medicines, and discloses application of a KIF20A expression inhibitor in preparation of a medicine for treating keloid. The KIF20A expression inhibitor is a substance capable of reducing mRNA (messenger ribonucleic acid) and / or protein level of KIF20A. The invention provides a novel medicine for treating keloid, the expression of targeted KIF20A can increase the apoptosis of keloid fibroblasts by causing keloid fibroblast G2 / M phase retardation, meanwhile, the migration ability of the keloid fibroblasts is reduced, and the medicine has a treatment effect on the keloid.

This invention describes methods for treating wound healing pathologies, inhibiting or reversing fibrotic skin disorders, including but not limited to keloids, atrophic and hypertrophic scars, and reversing skin aging via generating new dermal adipocytes (DAs). Methods described herein comprise (a) grafting of human hair follicles or (b) direct delivery of conditioned media from in vitro cultured hair follicles, or (c) delivery of purified individual factors secreted by hair follicles, or (d) delivery of small molecule agonists that mimic hair derived signaling activities, or (e) delivery of small molecule antagonists that inhibit anti-adipogenic programs, or (f) delivery of small molecule agonists of pro-adipogenic programs to convert endogenous wound or scar skin fibroblasts into new DAs.

The invention discloses application of defacitinib in preparation of a medicine for treating keloid, and belongs to the technical field of biological medicine. Aiming at the problems that a traditional keloid treatment method is poor in curative effect, high in risk, high in cost and the like, the invention provides application of defacitinib in preparation of the medicine for treating keloid, the medicine can effectively inhibit keloid fibroblast proliferation and migration, and a safe and convenient treatment means with reliable curative effect is provided for keloid, so that the medicine has a good application prospect. The invention has important social significance and clinical application value.

The invention provides a construction method of a humanized keloid mouse model. The construction method comprises the following steps: constructing and preparing BAC plasmids; carrying out superovulation and fertilized egg collection on the laboratory mice; carrying out pronucleus microinjection on the fertilized ova; embryo transplantation after injection; performing genotype identification; breeding and genetic analysis; and verifying the construction result of the humanized immune system by using immunohistochemistry and immunofluorescence. According to the invention, peripheral blood mononuclear cells treated by sCD27 and skin (homologous cells and tissues) around keloids are transplanted into a CD70 gene overexpressed NSG-MHC-DKO immune deficiency mouse body for the first time, so that HLA rejection possibly caused by different sources of immune cells and tissues is avoided; the internal microenvironment of the keloid and the interaction between the keloid and an immune system are restored to the greatest extent, and the influence of immune factors on the occurrence and development of the keloid can be researched in vitro. It is found and verified for the first time that activation of the CD27-CD70 axis can promote generation and development of keloids, and a suitable animal model is provided for research and development of anti-scar drugs, especially immunotherapy.

The invention relates to the technical field of biological medicines, in particular to application of a small-molecule inhibitor MYF-03-176 in preparation of a medicine for treating and / or preventing keloid and the medicine. The MYF-03-176 can remarkably promote fibroblast apoptosis of keloid tissue and inhibit cell proliferation, the volume of the keloid tissue can be remarkably reduced by locally injecting the MYF-03-176 into an animal, the MYF-03-176 is expected to become an effective drug choice for treating the keloid, and the combined treatment effect of the MYF-03-176 and the A-type botulinum toxin is further improved.

To provide methods for treatment and / or prevention of certain dermatological conditions, including hair graying, keloids and scleroderma.SOLUTION: A method comprises: providing a composition that comprises or delivers a plasminogen activator inhibitor-1 (PAI-1) inhibitor; and administering the composition to a site in a subject, where the site contains or once contained a plurality of hair follicles, each with a hair positioned therein, so that the PAI-1 inhibitor is delivered to the subject.SELECTED DRAWING: None

The utility model belongs to the technical field of scar treatment devices, and relates to a medical silica gel particle application device for keloid external radiotherapy, which comprises a base layer, the base layer is a self-adhesive medical transparent silica gel sheet, one side of the base layer is an adhesive surface attached to the skin, and the other side of the base layer is a non-adhesive surface; the non-sticky surface forms a marking surface and is provided with a particle positioning mark corresponding to the scar; the colloid layer is arranged at the particle positioning mark and forms a lattice structure; the covering layer is a self-adhesive medical transparent silica gel sheet, one side of the covering layer is an adhesive surface attached to the base layer, and the other side of the covering layer is an outward non-adhesive surface; the base layer and the covering layer form a closed interlayer, and the colloid layer is closed in the interlayer and is isolated from the skin. The medical silica gel particle application device for the keloid external radiotherapy has the advantages of simple structure and convenience in operation, and is particularly suitable for being used in primary hospitals.

This invention describes methods for treating wound healing pathologies, inhibiting or reversing fibrotic skin disorders, including but not limited to keloids, atrophic and hypertrophic scars, and reversing skin aging via generating new dermal adipocytes (DAs). Methods described herein comprise (a) grafting of human hair follicles or (b) direct delivery of conditioned media from in vitro cultured hair follicles, or (c) delivery of purified individual factors secreted by hair follicles, or (d) delivery of small molecule agonists that mimic hair derived signaling activities, or (e) delivery of small molecule antagonists that inhibit anti-adipogenic programs, or (f) delivery of small molecule agonists of pro-adipogenic programs to convert endogenous wound or scar skin fibroblasts into new DAs.

The application discloses application of a cytokine interleukin-17D (IL-17D) in preparation of a medicine for preventing and / or treating scars. IL-17D is highly expressed in fibroblasts, but is down-regulated in myofibroblasts in skin scars and keloids. Low expression of IL-17D makes IL-17D unable to inhibit expression of fibrosis-related genes, thus unable to inhibit differentiation of fibroblasts into myofibroblasts, thereby causing generation of scars. Overexpression of IL-17D or injection of recombinant IL-17D protein in a mouse full-thickness skin wound can significantly inhibit formation of scars; after IL-17D gene of the mouse is knocked out, expression of fibrosis-related genes in the skin wound is up-regulated, and scars after wound healing are obviously aggravated. Therefore, the application discloses that IL-17D can be used as a medicine for diagnosing and treating skin scars or keloids.

The method of preparation of biomass to support healing of hypertrophic scars and keloids, contains the steps: Culturing of mycelium of the filamentous fungus, Preparation of a pure culture of the filamentous fungus, Verification of the generic and species affiliation of the filamentous fungus, and Finalization of the biomass. The biomass produced in this way is deposited on a nanotechnology substrate in the form of a foil. Biomass according to this solution is suitable for supporting the healing of hypertrophic scars and keloids or to test medicinal substances intended for the skin.

Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic / injured area).

The invention belongs to the technical field of skin wound repair, and particularly relates to application of a compound in preparation of a scar relieving agent and an external scar removing agent. According to anti-scar traditional Chinese medicine prescription analysis and component and activity research, daucosterol, shikonin, przewalskin C and 4-ethoxyformyl-quinol-2-ketone have the effects of inhibiting proliferation of human keloid fibroblasts and inhibiting collagen synthesis of human normal skin fibroblasts induced by TGF-beta1; the composition has a scar relieving effect on scars of scar animal models, and can be used as a scar relieving agent, especially an external preparation applied to local skin. The invention further discloses an external scar-removing agent, namely an emulsion-type liniment, the main component of the external scar-removing agent contains silicone oil and also contains any one of an antioxidant and / or daucosterol, shikonin, przewalskin C and 4-ethoxyformyl-quinoline-2-ketone, and the main component has a better effect of relieving scars of a scar animal model when being externally applied to local skin.

This invention relates to compositions comprising APX3330 or an APX3330 hemicalcium salt monohydrate. The invention also provides methods for treating or preventing an ocular disease, an inflammatory disease, Barrett's esophagus (BE), cancer, a hepatic disease, a cardiovascular disease, idiopathic pulmonary fibrosis, a keloid, systemic sclerosis, chemotherapy-induced peripheral neuropathy, stroke, gastro-intestinal dysfunction, chronic gastroesophageal reflux disease, von Hippel-Lindau syndrome or a skin disorder; methods for inhibiting angiogenesis; methods for inhibiting vascular endothelial growth factor (VEGF) or VEGF protein expression; methods for inhibiting capillary tube formation; methods for suppressing neuronal sensitivity; methods for treating pain, methods for enhancing DNA base excision repair; and methods for enhancing neuronal DNA repair function; wherein each method comprises administering to a subject in need thereof an effective amount of a composition comprising APX3330 or an APX3330 hemicalcium salt monohydrate.